Form 4: Travere Therapeutics CFO Sells Shares to Cover Tax Obligations

Travere Therapeutics' Chief Financial Officer, Christopher R. Cline, sold 865 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Christopher R. Cline, the Chief Financial Officer of Travere Therapeutics, sold 865 shares of the company's common stock on January 22, 2025.
• The sale was executed at a price of $18.9409 per share.
• This transaction was not a discretionary trade but rather a 'sell to cover' transaction mandated by the company to cover tax withholding obligations related to vested restricted stock units.
• Following the transaction, Mr. Cline directly owns 73,730 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment regarding the company's performance.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, as they often need to sell shares to cover the associated tax liabilities.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are common among executives at publicly traded companies, particularly those who receive stock options or restricted stock units as part of their compensation.
• The number of shares sold and the price are specific to this individual and company, but the mechanism is standard practice.
• Comparable companies would likely have similar transactions by their executives.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the CFO's confidence in the company.

Key Dates

Keywords

Travere Therapeutics, Christopher R. Cline, CFO, stock sale, tax obligations, restricted stock units, sell to cover, insider trading